Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



Stephen Barton's Articles

Caldan Therapeutics Announces Key Appointment

 Edinburgh, UK – Caldan Therapeutics, a spin-out company from the Universities of Glasgow and Southern Denmark, which specialises in developing novel therapeutics targeting free fatty acid receptors for the treatment of metabolic disease, including Type 2 Diabetes and non-alcoholic steatohepatitis (NASH), is pleased to announce the appointment of Dr Mark Payton as Chief Executive Officer (CEO).

Summit Therapeutics to Participate in February Investor Conferences

Oxford, UK - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that company management will participate in three upcoming investor conferences taking place in New York City in February.

Chronos CEO awarded 2016 Best European CEO in the Drug Discovery Industry

Oxford, UK - Chronos Therapeutics Ltd (Chronos), the private biotech company focused on ageing diseases, brain and nervous system disorders, is honoured to announce that Dr Huw Jones, CEO of Chronos, has been awarded Best CEO in the European Drug Discovery Industry by online and print magazine European CEO.

Oxford Immunotec to Present at the Leerink Partners 6th Annual Global Healthcare Conference

Oxford, UK & Marlborough, USA - Oxford Immunotec Global PLC, a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced Richard Altieri, Chief Financial Officer, will present at the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017, at 10:00 a.m. EST at the Lotte New York Palace in New York City.

Summit Outline Phase 3 Programme for Novel CDI Antibiotic Ridinilazole

Oxford, UK – Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection (‘CDI’), today outlines its Phase 3 programme for its novel antibiotic, ridinilazole, following recent regulatory meetings with the US Food and Drug Administration (‘FDA’) and European Medicines Agency (‘EMA’).

Glide Technologies Announces Successful £3.2 Million ($4.0 Million) Fundraising

Oxford, UK – Glide Technologies, the pharmaceutical development and device company focused on the needle-free administration of solid dose formulations, today announced the successful completion of a funding round totalling £3.2 million ($4.0 million). The fundraising was supported by a number of existing investors.

OBN Announces Venner Shipley as New Corporate Sponsor

Abingdon, UK - OBN, the membership organisation supporting the UK’s innovative life sciences companies is pleased to announce today that Venner Shipley, a leading firm of European patent & trade mark attorneys and IP lawyers, has become OBN’s exclusive patent and trade mark attorney sponsor.

The Electrospinning Company Announces £650,000 Funding Round

Harwell, UK - The Electrospinning Company, announces that it has secured a £650,000 investment to establish itself as the leading provider of clinical-grade electrospun biomaterials to the medical device industry.  Funding has come from a network of UK angel investors, including Angels 5K, LBA, Minerva, Wroxall, Angels in MedCity and OION, as well as from the Rainbow Seed Fund.

Novo Nordisk Enters Collaboration with University of Oxford on Type 2 Diabetes and Invests £115m in New Research Centre

Oxford, UK & Bagsværd, Denmark­ ­- University of Oxford and Novo Nordisk today announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. As part of the collaboration, Novo Nordisk is also investing in a new research centre on the premises of the University of Oxford.

Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics

Alexandria & San Jose, USA and Oxford, UK – Oxford Finance LLC, an industry-leading specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced the closing of a $10 million senior secured term loan with Oxford BioTherapeutics (“OBT”), an international, clinical-stage biotechnology company focused on developing antibody-based therapies to treat cancer.

Pages: Previous1234567...12NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.